Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.

被引：0
|
作者：
Lowery, Maeve Aine
Abou-Alfa, Ghassan K.
Burris, Howard A.
Janku, Filip
Shroff, Rachna T.
Cleary, James M.
Azad, Nilofer Saba
Goyal, Lipika
Maher, Elizabeth A.
Gore, Lia
Hollebecque, Antoine
Beeram, Muralidhar
Trent, Jonathan C.
Jiang, Liewen
Ishii, Yuko
Auer, Julia
Gliser, Camelia
Agresta, Samuel V.
Pandya, Shuchi Sumant
Zhu, Andrew X.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4013
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
    DiNardo, Courtney D.
    De Botton, Stephane
    Stein, Eytan M.
    Roboz, Gail J.
    Mims, Alice S.
    Pollyea, Daniel A.
    Swords, Ronan T.
    Altman, Jessica K.
    Collins, Robert H.
    Mannis, Gabriel N.
    Uy, Geoffrey L.
    Donnellan, Will
    Pigneux, Arnaud
    Fathi, Amir T.
    Stein, Anthony S.
    Erba, Harry P.
    Prince, Gabrielle T.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Yen, Katharine
    Kapsalis, Stephanie M.
    Liu, Hua
    Goldwasser, Meredith
    Agresta, Sam
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [2] AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
    Mellinghoff, Ingo K.
    Touat, Mehdi
    Maher, Elizabeth
    DeLaFuente, Macarena
    Cloughesy, Timothy F.
    Holdhoff, Matthias
    Cote, Gregory
    Burris, Howard
    Janku, Filip
    Huang, Raymond
    Young, Robert
    Ellingson, Benjamin
    Auer, Julia
    Liu, Hua
    Hurov, Jonathan
    Yen, Katherine
    Agresta, Sam
    Attar, Eyal
    Pandya, Susan
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2016, 18 : 12 - 12
  • [3] TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort
    Yuan, J.
    Zheng, Y.
    Xu, L.
    Xie, F.
    Gu, S.
    Li, Q.
    Zhang, J.
    Ba, Y.
    Huaxin, D.
    Yang, A.
    Li, J.
    Zhou, J.
    Shen, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S120 - S120
  • [4] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
    Popovici-Muller, Janeta
    Lemieux, Rene M.
    Artin, Erin
    Saunders, Jeffrey O.
    Salituro, Francesco G.
    Travins, Jeremy
    Cianchetta, Giovanni
    Cai, Zhenwei
    Zhou, Ding
    Cui, Dawei
    Chen, Ping
    Straley, Kimberly
    Tobin, Erica
    Wang, Fang
    David, Muriel D.
    Penard-Lacronique, Virginie
    Quivoron, Cyril
    Saada, Veronique
    De Botton, Stephane
    Gross, Stefan
    Dang, Lenny
    Yang, Hua
    Utley, Luke
    Chen, Yue
    Kim, Hyeryun
    Jin, Shengfang
    Gu, Zhiwei
    Yao, Gui
    Luo, Zhiyong
    Lv, Xiaobing
    Fang, Cheng
    Yan, Liping
    Olaharski, Andrew
    Silverman, Lee
    Biller, Scott
    Su, Shin-San M.
    Yen, Katharine
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
  • [5] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Roboz, Gail J.
    Altman, Jessica K.
    Mims, Alice S.
    Swords, Ronan
    Collins, Robert H.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Donnellan, Will
    Fathi, Amir T.
    Pigneux, Arnaud
    Erba, Harry P.
    Prince, Gabrielle T.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Willekens, Christophe
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Yang, Hua
    Dai, David
    Fan, Bin
    Goldwasser, Meredith
    Liu, Hua
    Agresta, Sam
    Wu, Bin
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
  • [6] Phase I study of HC-1119, an androgen receptor inhibitor: Results from the dose escalation and expansion cohorts.
    Bi, Feng
    Zheng, Li
    Liu, Jiyan
    Cheng, Ke
    Chao, Peng
    Zhou, Yuwen
    Wei, Qiang
    Zeng, Hao
    Shen, Pengfei
    Shu, Zhengqing
    Zhou, Zhongxiu
    Zheng, Wei
    Chen, Yuanwei
    Li, Xinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
    Roboz, Gail J.
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Mims, Alice S.
    Prince, Gabrielle T.
    Altman, Jessica K.
    Arellano, Martha L.
    Donnellan, William B.
    Erba, Harry P.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Watts, Justin M.
    Fathi, Amir T.
    Kantarjian, Hagop M.
    Tallman, Martin S.
    Choe, Sung
    Dai, David
    Fan, Bin
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Hickman, Denice
    Liu, Hua
    Agresta, Samuel V.
    Wu, Bin
    Attar, Eyal C.
    Stone, Richard M.
    BLOOD, 2018, 132
  • [8] AG-120 (ivosidenib), a first in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
    Ishii, Yuko
    Sigel, Carlie
    Lowery, Maeve A.
    Goyal, Lipika
    Gliser, Camelia
    Jiang, Liewen
    Pandya, Susan
    Bin Wu
    Choe, Sung
    Deshpande, Vikram
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [9] PHARMACOKINETIC/PHARMACODYNAMIC EVALUATION OF AG-120, A POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF IDH1-MUTANT ADVANCED HEMATOLOGIC MALIGNANCIES
    Fan, B.
    Chen, Y.
    Wang, F.
    Yen, K.
    Utley, L.
    Prahl, M.
    Colby, K.
    Straley, K.
    Bowden, C.
    Biller, S.
    Agresta, S.
    Yang, H.
    HAEMATOLOGICA, 2015, 100 : 218 - 218
  • [10] Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
    Foran, James M.
    DiNardo, Courtney D.
    Watts, Justin M.
    Stein, Eytan M.
    De Botton, Stephane
    Fathi, Amir T.
    Prince, Gabrielle T.
    Stein, Anthony
    Stone, Richard M.
    Patel, Prapti A.
    Tallman, Martin S.
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Fan, Bin
    Yen, Katharine E.
    Oluyadi, Abdulafeez
    Winkler, Thomas
    Hickman, Denice
    Agresta, Samuel V.
    Liu, Hua
    Wu, Bin
    Attar, Eyal C.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
12345